Browse the evidence

Parameters of glucose metabolism improved along with psychological indicators of eating impulses.

Improving glucose metabolism and psychological factors can enhance weight loss strategies.

Early genetic diagnostics can identify the type of obesity and guide therapy options.

Implementing genetic testing can enhance personalized treatment strategies for obesity.

Obesity is a chronic disease with significant physical and psychological impairments.

Practitioners should recognize obesity as a serious chronic condition requiring comprehensive management.

There is increasing acceptance of anti-obesity medications as an adjunct to lifestyle modifications and/or surgery.

Practitioners should consider integrating pharmacotherapy with lifestyle changes and surgical options for comprehensive obesity management.

There is an urgent need for a structured, customized and evidence-based clinical practice guideline for the management of obesity in Bangladesh.

Practitioners should advocate for and implement structured guidelines for obesity management.

GLP-1 agonists improve blood glucose profiles and reduce cardiovascular risk.

GLP-1 agonists can be recommended for improving glycemic control and reducing cardiovascular risks in diabetic patients.

Dual GIP/GLP-1 agonists are more effective in treating obesity than GLP-1 agonists alone.

Consider dual GIP/GLP-1 agonists for potentially better outcomes in obesity treatment.

Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).

Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.

Serious adverse events were lower in the semaglutide group (13.3%) compared to the placebo group (26.7%) (P < .001).

Semaglutide may offer a safer treatment option for this patient population.

Ultrasonography is a reliable and affordable tool for measuring fat and muscle mass.

Practitioners can consider ultrasonography for better assessment of body composition in patients.

As muscle mass decreases, the risk of conditions like type 2 diabetes rises.

Addressing muscle mass in obesity management could improve health outcomes.

The current Russian clinical guidelines for the treatment of obesity include drugs such as orlistat, sibutramine, and liraglutide.

Clinicians should be aware of the current guidelines when prescribing treatments for obesity.

There is a need to expand existing clinical recommendations for the treatment of patients with obesity.

Healthcare providers should consider integrating new pharmacotherapies into their treatment plans for obesity.

MR-O and Conv-O similarly increased fecal fat percentage from 3.8% to 13.5%, confirming pharmacodynamic equivalence.

Both formulations can be considered equally effective in increasing fecal fat excretion.

The new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O.

MR-OA can be expected to function similarly to Conv-O in promoting fat loss.

Psychological capabilities and reflective motivation have direct effects on the frequency of resistance training participation among GLP-1 medication users.

Practitioners should focus on enhancing psychological capabilities and motivation to improve resistance training frequency in GLP-1 users.

Psychological capabilities directly or indirectly influence all resistance training participation characteristics among GLP-1 medication users.

Enhancing psychological capabilities is crucial for improving overall resistance training participation.

Co-stimulation of GLP-1 with other receptors provides additional therapeutic benefits.

Combining GLP-1 therapy with other hormonal treatments may enhance effectiveness.

Obesity-related hypertension is a significant contributor to cardiovascular morbidity and mortality.

Healthcare providers should prioritize addressing obesity to mitigate hypertension and related cardiovascular risks.

Behavioral support is necessary to maximize the benefits of incretin therapy.

Practitioners should integrate behavioral support strategies into incretin therapy plans.

Recent studies highlight the efficacy of diabetic agents and other novel therapies in shaping obesity-associated hypertension management guidelines.

Healthcare providers should consider incorporating diabetic agents and novel therapies into treatment plans.

Both 0839 and 0833 improved metabolic parameters and reduced body weight primarily by fat mass reduction.

These compounds may be effective for fat loss and improving metabolic health.

Übergewicht erhöht die Häufigkeit von Beckenbodenfunktionsstörungen, wobei ein höherer BMI mit einer höheren Prävalenz von Harn- und Stuhlinkontinenz sowie Genitaldeszensus korreliert.

Praktiker sollten Übergewicht als Risikofaktor für Beckenbodenfunktionsstörungen bei Frauen berücksichtigen.

Bei Schwangeren kann Übergewicht das Risiko für postpartale Beckenbodenstörungen deutlich erhöhen.

Praktiker sollten prä- und postpartale Maßnahmen zur Beckenbodengesundheit bei übergewichtigen Schwangeren priorisieren.